Cargando…

Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability

BACKGROUND AND AIMS: Obese and diabetic mice display enhanced intestinal permeability and metabolic endotoxaemia that participate in the occurrence of metabolic disorders. Our recent data support the idea that a selective increase of Bifidobacterium spp. reduces the impact of high-fat diet-induced m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cani, P D, Possemiers, S, Van de Wiele, T, Guiot, Y, Everard, A, Rottier, O, Geurts, L, Naslain, D, Neyrinck, A, Lambert, D M, Muccioli, G G, Delzenne, N M
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2009
Materias:	Inflammatory bowel disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702831/ https://www.ncbi.nlm.nih.gov/pubmed/19240062 http://dx.doi.org/10.1136/gut.2008.165886

Ejemplares similares

The role of gut microbiome in inflammatory bowel disease diagnosis and prognosis
por: Zheng, Jiaying, et al.
Publicado: (2022)

Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo
por: Massimino, Luca, et al.
Publicado: (2023)

Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD
por: Lee, Thomas, et al.
Publicado: (2017)

Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse
por: Arrieta, M C, et al.
Publicado: (2008)

Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo
por: Fischer, Anika, et al.
Publicado: (2016)

Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition
por: Binion, D G, et al.
Publicado: (2008)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial
por: Feagan, B. G., et al.
Publicado: (2016)

Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease
por: Kiesslich, R, et al.
Publicado: (2011)

The endocannabinoid system links gut microbiota to adipogenesis
por: Muccioli, Giulio G, et al.
Publicado: (2010)

Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
por: Sandborn, W. J., et al.
Publicado: (2015)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study
por: Murthy, Sanjay K, et al.
Publicado: (2020)

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
por: Panés, Julian, et al.
Publicado: (2017)

Validation of stricture length, duration and obstructive symptoms as predictors for intervention in ileal stricturing Crohn's disease
por: El Ouali, Sara, et al.
Publicado: (2022)

Endoscopy and histology in inflammatory bowel diseases patients: Complementary or alternatives?
por: D'Amico, Ferdinando, et al.
Publicado: (2022)

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
por: Hébuterne, Xavier, et al.
Publicado: (2013)

Quality of life in patients with IBD during the COVID-19 pandemic in the Netherlands
por: de Bock, Ellen, et al.
Publicado: (2021)

Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study
por: Clooney, Adam G, et al.
Publicado: (2021)

Polygenic risk score predicts risk of primary sclerosing cholangitis in inflammatory bowel disease
por: Wang, Ming-Hsi, et al.
Publicado: (2023)

Landscape of new drugs and targets in inflammatory bowel disease
por: Vieujean, Sophie, et al.
Publicado: (2022)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Smoking and colorectal neoplasia in patients with inflammatory bowel disease: Dose‐effect relationship
por: Wijnands, Anouk M., et al.
Publicado: (2023)

High prevalence of ulcerative appendicitis in patients with ulcerative colitis
por: Heuthorst, Lianne, et al.
Publicado: (2021)

Developing a core outcome set for fistulising perianal Crohn’s disease
por: Sahnan, Kapil, et al.
Publicado: (2019)

Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse
por: Robinson, A, et al.
Publicado: (2013)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers
por: Roberts, Carol L, et al.
Publicado: (2010)

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study
por: Sandborn, William J, et al.
Publicado: (2018)

Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study
por: Allocca, Mariangela, et al.
Publicado: (2022)

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis
por: Brookes, Matthew J, et al.
Publicado: (2020)

Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease: Results of the HOT‐TOPIC trial after 1‐year follow‐up
por: Lansdorp, Corine A., et al.
Publicado: (2022)

Ulcerative colitis: Impact of early disease clearance on long‐term outcomes ‐ A multicenter cohort study
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Panenteric capsule endoscopy versus ileocolonoscopy plus magnetic resonance enterography in Crohn’s disease: a multicentre, prospective study
por: Bruining, David Henry, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g7v0a33sj3sspktraioh5aj6fg